Treatment strategies effective in bradykinin-mediated angioedema are mainly approved for the hereditary forms and include on-demand therapy for the treatment of acute attacks, short-term prophylaxis (STP) to prevent attacks during high-risk procedures such as surgical interventions, dental surgery, endotracheal intubation, bronchoscopy, or esophagogastroduodenoscopy; and long-term prophylaxis (LTP), in patients with frequent attacks in order to reduce the burden of disease [11,13]. This evidence concerns the gene KNG1 and angioedema.